Jacobs backs FY25 adjusted EPS view $5.85-$6.20, consensus $6.03

Backs FY25 revenue view up mid-to-high single digits. Backs FY25 adjusted EBITDA margin view 13.8%-14%. The company said, “We returned record amounts of capital back to shareholders in the first half of the year, repurchasing $351 million of our shares in Q2 2025 and $552 million in H1 2025, demonstrating our commitment to capital returns. We also retired $312 million in debt via an equity for debt exchange using our stake in AMTM, and refinanced approximately $700 million of existing debt at a lower interest rate, putting our balance sheet in excellent shape exiting Q2 2025. Subsequent to Q2 2025 close, we successfully completed a key milestone in connection with the separation of the former CMS and C&I businesses by finalizing the post-closing adjustment to working capital, enabling incremental debt reduction during Q3 2025, and receiving Board approval to distribute the remaining Amentum shares to our shareholders on May 30th.”